{"id":"mmrvaxpro","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Fever"},{"rate":"5","effect":"Rash"},{"rate":"10-20","effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":"<1","effect":"Parotitis (mumps-like symptoms)"},{"rate":"1-3","effect":"Arthralgia/arthritis"}]},"_chembl":{"chemblId":"CHEMBL6068354","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease. This triggers both humoral (antibody-mediated) and cell-mediated immune responses, providing long-term protection against these three viral infections. The attenuated viruses are unable to cause the severe manifestations of wild-type infection while still generating robust immunological memory.","oneSentence":"MMRvaxpro is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:34.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles, mumps, and rubella in children and adults"}]},"trialDetails":[{"nctId":"NCT03780179","phase":"PHASE4","title":"MMR at 6 Months Trial","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-04-15","conditions":"Meales-mumps-rubella Vaccine","enrollment":6540}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BREECH PRESENTATION"},{"count":1,"reaction":"BRONCHIOLITIS"},{"count":1,"reaction":"HIP DYSPLASIA"},{"count":1,"reaction":"MATERNAL DRUGS AFFECTING FOETUS"},{"count":1,"reaction":"THELITIS"},{"count":1,"reaction":"TRANSIENT TACHYPNOEA OF THE NEWBORN"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MMRvaxpro","genericName":"MMRvaxpro","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Biologic","firstApprovalDate":"","aiSummary":"MMRvaxpro is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}